Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: A prospective controlled study

Journal of Viral Hepatitis

Volumn 15, Issue 9, 2008, Pages 684-689

  Luo, K ^a   Mao, Q ^b   Karayiannis, P ^c   Liu, D ^a   Liu, Z ^a   Zhou, Y ^a   Feng, X ^a   Zhu, Y ^a   Guo, Y ^a   Jiang, R ^a   Zhou, F ^a   Peng, J ^a   Hou, J ^a  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b University of Xiamen   (China)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic hepatitis B; HBeAg positive; Interferon alpha; Long term follow up; Tailored regimen

Indexed keywords

ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SEROCONVERSION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 49649109902     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00995.x     Document Type: Article

References (26)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004 11 : 97 107.
2. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990 323 : 295 301.
3. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988 95 : 1318 1325.
4. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991 114 : 629 634.
5. Carreño V, Castillo I, Molina J et al. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992 15 : 102 106.
6. Lin SM, Sheen IS, Chien RN et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999 29 : 971 975.
7. Lok AS, Chung HT, Liu VW et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993 105 : 1833 1838.
8. Di Bisceglie AM, Fong TL, Fried MW et al. A randomized, controlled trial of recombinant α-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993 88 : 1887 1892.
9. Wong DK, Cheung AM, O'Rourke K et al. Effect of alpha interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993 119 : 312 323.
10. Martin P, Hann HW, Westerberg S et al. Interferon-alpha2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial. Dig Dis Sci 1998 43 : 875 879.
11. Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001 34 : 139 145.
12. Lok ASF, McMahon BJ. Chronic hepatitis B: AASLD Practice Guidelines. Hepatology 2001 34 : 1225 1241.
13. Ma W, LU J, Jiang X et al. The therapeutic efficacy of recombinant interferon alfa-1b for the treatment of chronic hepatitis B and its predictive factors. (Abstract in English). Chin J Infect Dis 2001 19 : 148 151.
14. Janssen HLA, Gerken G, Carreno V et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology 1999 30 : 238 243.
15. Orlent H, Hansen BE, Willems M et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol 2006 45 : 539 546.
16. Rino Y, Tarao K, Morinaga S et al. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. Anticancer Res 2006 26 (3B 2221 2226.
17. Luo K, Liu Z, He H et al. The putative recombination of hepatitis B virus genotype B with pre-C/C of genotype C. Virus Genes 2004 29 : 31 41.
18. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 699.
19. Lok ASF, McMahon BJ. Chronic hepatitis B: AASLD Practice Guidelines. Hepatology 2007 45 : 507 539.
20. Lau GKK, Piratvisuth T, Luo KX et al. Peginterferon alfa-2a as monotherapy and in combination with lamivudine versus lamivudine monotherapy in patients with HBeAg-positive chronic hepatitis B. N Engl J Med 2005 352 : 2682 2695.
21. Lampertico P, Del Ninno E, Manzin A et al. A randomized, controlled trial of a 24-month course course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997 26 : 1621 1625.
22. Cooksley WGE, Pirarvisuth T, Lee SD et al. Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003 10 : 298 305.
23. Perrillo RP. Therapy of hepatitis B - viral suppression or eradication? Hepatology 2006 43 : S182 S193.
24. Luo K, He H, Mao Q et al. No significant differences in histology and response to interferon treatment in hepatitis B carriers of genotypes C and recombinant B. J Viral Hepat 2007 14 : 419 425.
25. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996 334 : 1422 1427.
26. van Zonneveld M, Honkoop P, Hansen BE et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004 39 : 804 810.